Abstract 109P
Background
Stable disease (SD) upon treatment with immune checkpoint inhibitors is generally associated with poorer survival outcomes than partial (PR) or complete response (CR). Yet, in the KEYNOTE-001 and -006 cohort, approximately half of patients with initial SD subsequently developed an objective response (OR) with improved survival outcomes. We present a real-world analysis of the prognosis of unresectable melanoma patients with SD at first evaluation after initiation of anti-PD-1 monotherapy.
Methods
The Danish Metastatic Melanoma Database (DAMMED) is a nation-wide registry on all Danish patients with unresectable melanoma eligible for systemic therapy. All patients diagnosed with unresectable cutaneous or unknown primary melanoma treated with single agent anti-PD-1 therapy, regardless of treatment line, were selected for analysis.
Results
1052 patients, treated between July 2014 and April 2022, were found eligible for analysis. At the initial evaluation, approximately 12 weeks after first anti-PD-1 administration, 232 patients (22.1%) had SD. Of these, 66 (28.4%) patients were alive and progression-free after a median follow up of 38.0 months while 87 (37.5%) later achieved PR (45) or CR (42). Overall, patients with initial SD had a median progression free survival (PFS) of 13.7 months and a median overall survival (OS) of 43.0 months. Grouping patients with initial SD by best overall response (BOR) revealed significantly different survival curves (p<0.001 for SD vs PR vs CR for both PFS and OS). In contrast, no significant differences were found when comparing the survival curves of patients with initial SD and subsequent OR to those of patients with initial OR (PFS: p=0.46 and p=0.83 for PR and CR, respectively; OS: p=0.69 and p=0.81, respectively). OS of patients with BOR SD was significantly better than the OS of patients with immediate PD (p<0.001).
Conclusions
More than one-third of patients with initial SD later obtain an OR with a prognosis similar to patients having the corresponding OR on first evaluation. Durable disease control is a common outcome following initial SD to anti-PD-1 monotherapy in melanoma.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
I.M. Noringriis: Financial Interests, Institutional, Research Grant, Research granted to our institution in order to initiate a biobank containing blood samples from patients with immune related adverse events. I am the principle investigator of the protocol: Sygeforsikringen, Novo Nordisk Fonden. M. Donia: Financial Interests, Personal, Other, Advisor: Achilles Therapeutics; Non-Financial Interests, Personal, Other, Sub-investigator of clinical trial with connected translational research: Bristol Myers Squibb; Non-Financial Interests, Personal, Proprietary Information, Proprietary data access: Bristol Myers Squibb; Non-Financial Interests, Personal, Proprietary Information, Proprietary data access: Genentech; Other, Personal, Other, Chairman of the Melanoma and Non-melanoma Skin Cancer Scientific Committee: Danish Medicines Council (Medicinrådet). L. Bastholt: Non-Financial Interests, Personal, Advisory Role, Scientific committee under Danish Medicines Agency regarding new treatments of melanoma, skin cancer and thyroid cancer: Danish Medicines Agency. C.A. Haslund: Financial Interests, Personal, Invited Speaker: MSD, GSK, BMS; Financial Interests, Institutional, Local PI: BMS, Tesaro, MSD, IO Biotech, Chimerix, Incyte; Financial Interests, Institutional, Coordinating PI: GSK, Celgene Aps. E. Ellebæk: Financial Interests, Personal, Invited Speaker: Pierre Fabre, BMS, Novartis, MSD, Pfizer; Other, Personal, Other, Travel and conference expenses: MSD, Pierre Fabre. I. Svane: Financial Interests, Personal, Advisory Board: BMS, Pierre Fabre, Novartis; Financial Interests, Personal, Invited Speaker: MSD, Pierre Fabre, Novartis, Roche, BMS; Financial Interests, Personal, Writing Engagement: MSD; Financial Interests, Personal, Stocks/Shares, Cofounder and Founder warrents: IO Biotech; Financial Interests, Institutional, Research Grant: Adaptimmune, Enara Bio, Lytix Biopharma, TILT Biotherapeutics; Financial Interests, Institutional, Funding: Evaxion; Non-Financial Interests, Personal, Principal Investigator: BMS, Novartis, Roche, TILT Biotherapeutics, Lytix Biopharma. All other authors have declared no conflicts of interest.
Resources from the same session
35P - Peripheral immunotype classification for monitoring Soft Tissue Sarcoma patients
Presenter: Jani Sofia Almeida
Session: Poster Display
36P - Expression of germinal center B cell- and Th17 cell-related transcripts are prognostic of soft-tissue sarcoma patient outcomes
Presenter: Giulia Petroni
Session: Poster Display
38P - Machine learning-based pathomics model to predict the infiltration of Treg and prognosis in IDH-wt GBM
Presenter: Shaoli Peng
Session: Poster Display
40P - The role of low avidity tumour-specific CD8+ T cells in immunotherapeutic response to anti-PD-1
Presenter: Doreen Lau
Session: Poster Display
41P - Contrasting drivers of response to immunotherapy across solid tumour types: results from analysis of >2500 cases
Presenter: Danwen Qian
Session: Poster Display
42P - TCCIA: A Comprehensive Resource for Exploring CircRNA in Cancer Immunotherapy
Presenter: Jian-Guo Zhou
Session: Poster Display
43P - Immune and tumor cells expression of VISTA in a panel of cancer indications: A strategy to inform selection of patients treated with anti-VISTA
Presenter: Pierre Launay
Session: Poster Display
44P - Exploratory Analysis of Peripheral Pharmacodynamic (PD) Biomarkers After Sitravatinib (Sitra) and Tislelizumab (TIS) in Advanced Solid Tumors: SAFFRON-103
Presenter: Yi-Long Wu
Session: Poster Display
45P - Protein biomarkers associated with organ-specific immune-related toxicity and response to management identified by proteome analysis of extracellular vesicles from plasma
Presenter: Anders Kverneland
Session: Poster Display